BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Okuvision GmbH Researcher to Present Clinical Trial Data at EURETINA Annual Congress


9/5/2012 9:58:06 AM

MILAN, Sept. 5, 2012 /PRNewswire/ -- Okuvision GmbH, the leading developer of transcorneal electrical stimulation (TES) therapy for patients with early-to mid-stage retinitis pigmentosa (RP) today announced that results from the Company's human clinical trial will be shared at the 12th EURETINA Congress, in Milan, 6-9 September. The abstract titled "Effects of Transcorneal Electrical Stimulation in Patients with Retinitis Pigmentosa" will be presented by Dr. Tobias Roeck from the Centre for Ophthalmology at the University of Tuebingen, on Friday, 7 September at 17:50 CEST. The presentation will focus on the impact of treatment with the Company's OkuStim® TES technology and the trial results achieved to-date.

"While recent clinical trials have shown promise for retinal implants to restore vision to patients with late stage RP, treatments for early to mid-stage RP patients have not historically been as successful," said Dr. Tobias Roeck, consultant at the Centre for Ophthalmology of the University of Tuebingen, Germany. "The patients in Okuvision's clinical trial saw a meaningful increase in their field of vision after receiving 150 percent of their perceived threshold of stimulation for six weeks. We're pleased with what we've been able to achieve thus far and look forward to further studying this technology and sharing our findings with the ophthalmic community at EURETINA."

Okuvision's CE marked OkuStim technology delivers physician-directed levels of TES to RP patients, with the goal of slowing the progression of RP-related blindness. During treatment, patients may feel a slight sensation, but no discomfort or pain is involved in the treatment. The results of Okuvision's pilot study were published in June 2011 issue of Investigative Ophthalmology and Visual Science and demonstrated that patients receiving stimulation showed a statistically significant improvement in their field of vision.

To add to the body of scientific evidence on the OkuStim technology, Okuvision is launching additional, studies of the technology. Taking place in Tuebingen, the EST2 study will test three levels of stimulation with OkuStim over a one-year period. TESOLA, a post-market multi-center research study in Europe, is also scheduled to begin in September 2012.

"We are encouraged by the results our patients have achieved thus far using the OkuStim technology," said Reinhard Rubow, CEO of Okuvision GmbH. "Our team looks forward to working with clinicians to continue building on what we know about the impact of OkuStim therapy so we can determine the impact of long-term use as well as the optimal level of stimulation patients should receive."

Congress attendees can learn more about Okuvision's OkuStim technology by visiting the Company's booth #P393.

About Okuvision GmbH

Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of transcorneal electrical stimulation (TES) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina Implant AG's subretinal implant technology, Okuvision was founded with the goal of testing and developing a treatment option aimed at delaying the effects of retinitis pigmentosa.

Okuvision's first study began in 2007 and treated 24 patients over a period of six weeks.

To learn more, please visit: www.okuvision.de.

Schwartz MSL:

Okuvsion GmbH:

Charlotte Webber

Reinhard Rubow

+44 7949 872296

+49 7121 36403 100

Okuvision@SchwartzMSL.com

Reinhard.Rubow@okuvision.de

SOURCE Okuvision GmbH



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES